These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32449261)

  • 1. Conducting prospective sequential surveillance in real-world dynamic distributed databases.
    Maro JC; Eworuke E; Hou L; Welch EC; Goulding MR; Izem R; Lee JY; Toh S; Fireman B; Nguyen MD
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1331-1335. PubMed ID: 32449261
    [No Abstract]   [Full Text] [Related]  

  • 2. Today's FDA.
    Slater EE
    N Engl J Med; 2005 Jan; 352(3):293-7. PubMed ID: 15659733
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety in numbers--monitoring risk in approved drugs.
    Okie S
    N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
    [No Abstract]   [Full Text] [Related]  

  • 4. Opening Pandora's pillbox: using modern information tools to improve drug safety.
    Gottlieb S
    Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA restructures new product review centers.
    Bouchie A
    Nat Biotechnol; 2002 Oct; 20(10):960. PubMed ID: 12355100
    [No Abstract]   [Full Text] [Related]  

  • 6. The US Food and Drug Administration's Real-World Evidence Framework: A Commitment for Engagement and Transparency on Real-World Evidence.
    ElZarrad MK; Corrigan-Curay J
    Clin Pharmacol Ther; 2019 Jul; 106(1):33-35. PubMed ID: 30883700
    [No Abstract]   [Full Text] [Related]  

  • 7. How pharmaceuticals are developed.
    Vander Elst E
    J Am Dent Assoc; 1994 Jan; 125 Suppl():40S-44S. PubMed ID: 8294674
    [No Abstract]   [Full Text] [Related]  

  • 8. Developing the Sentinel System--a national resource for evidence development.
    Behrman RE; Benner JS; Brown JS; McClellan M; Woodcock J; Platt R
    N Engl J Med; 2011 Feb; 364(6):498-9. PubMed ID: 21226658
    [No Abstract]   [Full Text] [Related]  

  • 9. Information Patients Can Provide Will Strengthen the Real-World Evidence That Matters to Them.
    Nowell WB
    Clin Pharmacol Ther; 2019 Jul; 106(1):49-51. PubMed ID: 31112287
    [No Abstract]   [Full Text] [Related]  

  • 10. Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval.
    Wallach JD; Zhang AD; Skydel JJ; Bartlett VL; Dhruva SS; Shah ND; Ross JS
    JAMA Netw Open; 2021 Nov; 4(11):e2133667. PubMed ID: 34751763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database.
    Mott K; Graham DJ; Toh S; Gagne JJ; Levenson M; Ma Y; Reichman ME
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1023-32. PubMed ID: 27146123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What ails the FDA?
    Okie S
    N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660
    [No Abstract]   [Full Text] [Related]  

  • 13. Avoiding the regulatory capture of the Food and Drug Administration.
    Egilman DS; Presler AH; Valentin CS
    Arch Intern Med; 2007 Apr; 167(7):732-3. PubMed ID: 17420438
    [No Abstract]   [Full Text] [Related]  

  • 14. The US Food and Drug Administration's Model-Informed Drug Development Paired Meeting Pilot Program: Early Experience and Impact.
    Madabushi R; Benjamin JM; Grewal R; Pacanowski MA; Strauss DG; Wang Y; Zhu H; Zineh I
    Clin Pharmacol Ther; 2019 Jul; 106(1):74-78. PubMed ID: 31081932
    [No Abstract]   [Full Text] [Related]  

  • 15. Paying for drug approvals--who's using whom?
    Avorn J
    N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA's first active medical product surveillance eyes antidiabetic-MI link.
    Thompson CA
    Am J Health Syst Pharm; 2011 Apr; 68(7):550-1. PubMed ID: 21411791
    [No Abstract]   [Full Text] [Related]  

  • 17. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.
    Robb MA; Racoosin JA; Sherman RE; Gross TP; Ball R; Reichman ME; Midthun K; Woodcock J
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():9-11. PubMed ID: 22262587
    [No Abstract]   [Full Text] [Related]  

  • 18. Advances in the Use of Real-World Evidence for Medical Devices: An Update From the National Evaluation System for Health Technology.
    Fleurence RL; Shuren J
    Clin Pharmacol Ther; 2019 Jul; 106(1):30-33. PubMed ID: 30888048
    [No Abstract]   [Full Text] [Related]  

  • 19. Tuft's report backs FDA fast-track, but post-marketing concerns loom.
    Vastag B
    Nat Biotechnol; 2006 May; 24(5):478. PubMed ID: 16680113
    [No Abstract]   [Full Text] [Related]  

  • 20. Detecting software failures in the MAUDE database: a preliminary analysis.
    Pecoraro F; Luzi D
    Stud Health Technol Inform; 2013; 192():1098. PubMed ID: 23920872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.